ArticleFrontiers in allergy2026
Incidence rates of allergy diagnoses in the U.S. military health system after the COVID-19 pandemic.
Article in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: During the COVID-19 pandemic, exposures to environmental allergens and microorganisms were dramatically altered, potentially impacting the development and diagnosis of allergic conditions. Methods: We conducted a retrospective, repeated, monthly cross-sectional study examining monthly incidence rates of allergic diseases diagnosed before and throughout the first 3 years of the COVID-19 pandemic in individuals aged 0-64 years enrolled in the TRICARE Management Activity Military Health System (MHS) Data Repository (MDR). Allergic diseases were grouped into twelve categories. Rates of incident outcomes were calculated monthly and compared between subgroups and during the pre-pandemic year (March 1, 2019-February 29, 2020) and the first 3 years after the COVID-19 Pandemic beginning on March 1, 2020. Results: Allergy diagnoses of all twelve conditions assessed were lower during COVID-19 year 1 (incidence 430 per 100,000) compared with the pre-pandemic year (incidence 750 per 100,000). This reduction in allergic diagnoses during COVID-19 year 1 was statistically significant for all allergic diagnoses queried. During COVID-19 years 2 and 3, allergy diagnoses of all conditions, except for anaphylaxis and food protein induced enterocolitis syndrome (FPIES) remained lower compared with the pre-pandemic year. The decrease in allergic diagnoses was greater than the decrease in total MHS healthcare visits. Discussion: In the MHS, for the first 3 years of the COVID-19 pandemic, allergic diagnoses were lower than in year prior to the pandemic. This reduction cannot be fully explained by decreased healthcare utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.